Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | F13A1 | P00488 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28421444 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL28421388 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL28413601 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL28415269 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL28421401 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL503569 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL28417932 | 0.98 | MAPT (0.59) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL197022 | 0.94 | HDAC3 (0.57) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL7434059 | 0.93 | HDAC3 (0.55) | MAPTRXFP1F13A1HDAC3HDAC4 | |
| SCHEMBL27754704 | 0.87 | MPO (0.44) | MAPTRXFP1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107592865-A | Peptidomimetic compounds for neutralizing influenza viruses | 扬森疫苗与预防公司 | 2018-01-16 | — | — | CN | claimed |
| CN-102405229-A | Short-chain peptides as parathyroid hormone (PTH) receptor agonists | CADILA HEALTHCARE LTD | 2012-04-04 | — | — | CN | claimed |
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| CN-110536696-B | PCSK9 vaccine based on novel peptides | 载度思生命科学有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-113490682-A | Antimicrobial peptides and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-106749373-B | Rubber additive and preparation and application thereof | 同济大学 | 2020-06-26 | — | — | CN | disclosed |
| US-20190359653-A1 | SELECTIVE PEPTIDE INHIBITORS OF FRIZZLED | GENENTECH INC (US) | 2019-11-28 | — | — | US | disclosed |
| CN-110494167-A | Composition and system for renal function measurement | MEDIBEACON INC | 2019-11-22 | — | — | CN | disclosed |
| CN-110461332-A | METHOD FOR PREPARING AND ANALYZING FLUORESCENT COMPOUNDS IN PLASMA | MEDIBEACON INC | 2019-11-15 | — | — | CN | disclosed |
| EP-3509616-A1 | SELECTIVE PEPTIDE INHIBITORS OF FRIZZLED | H. Hoffnabb-La Roche Ag (CH) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049275-A1 | SELECTIVE PEPTIDE INHIBITORS OF FRIZZLED | GENENTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| CN-1125818-C | Amino acid derivatives of substituted quinoxaline 2, 3 -dione derivativesa as glutamate receptor antagonists | WARNER LAMBERT CO (US) | 2003-10-29 | — | — | CN | disclosed |
| US-20030032774-A1 | Novel opioid peptides for the treatment of pain | ASTRAZENECA AB | 2003-02-13 | — | — | US | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| CN-1040432-C | Spiro piperdines and homologs promote release of growth hormone | MERCK & CO INC (US) | 1998-10-28 | — | — | CN | disclosed |
| CN-1187190-A | Amino acid derivatives of substituted quinoxaline 2, 3-dione derivatives as glutamate receptor antagonists | WARNER LAMBERT CO (US) | 1998-07-08 | — | — | CN | disclosed |
| CN-1092767-A | Promote spiroperidol and homologue that tethelin discharges | MERCK & CO INC (US) | 1994-09-28 | — | — | CN | disclosed |
| US-4658013-A | CONTAINING ALANINE, PHENYLALANINE AND/OR TYROSINE OR METHIONINE | STERLING DRUG INC. (US) | 1987-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032774-A1 | Novel opioid peptides for the treatment of pain | OPRL1, OPRK1, OPRM1 | MAPT 1279/4885RXFP1 27/4885F13A1 404/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | MAPT 763/4885RXFP1 202/4885F13A1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.